Peking University (Beijing, China) and Boehringer Ingelheim GmbH (Ingelheim, Germany) entered into a broad partnership under which they plan to identify targets and develop therapies in cancer, cancer immunology and immune modulation, respiratory, cardiometabolic and CNS diseases. The partners will also seek to develop regenerative medicines and gene therapies. Boehringer said the partnership will last four years with a possible extension. Boehringer declined to disclose financial terms.
The collaboration is Boehringer's second recent research partnership with a Chinese university. In November 2016, Boehringer collaborated with the China Southeast University Institute of Life Sciences (Nanjing, China) to develop regenerative therapies to treat hearing loss (see BioCentury, Dec. 2, 2016)...